Clonidine
- Generic Name
- Clonidine
- Brand Names
- Catapres, Catapres-TTS, Catapres-tts-1, Duraclon, Kapvay, Nexiclon XR
- Drug Type
- Small Molecule
- Chemical Formula
- C9H9Cl2N3
- CAS Number
- 4205-90-7
- Unique Ingredient Identifier
- MN3L5RMN02
- Background
Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.
Clonidine was granted FDA approval on 3 September 1974.
- Indication
Clonidine tablets and transdermal systems are indicated for the treatment of hypertension alone or in combination with other medications. A clonidine injection is indicated for use with opiates in the treatment of severe cancer pain where opiates alone are insufficient. An extended release tablet of clonidine is indicated for the treatment of ADHD either alo...
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Defiant Disorder, Oppositional, Gilles de la Tourette's Syndrome, Hot Flashes, Human Growth Hormone Deficiency, Hypertension, Opioid Withdrawal (Disorder), Pheochromocytoma, Postherpetic Neuralgia, Sialorrhea caused by clozapine, Diabetic diarrhea, Methadone withdrawal, Severe Cancer pain
- Associated Therapies
- Smoking, Cessation
Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage
- Conditions
- First Posted Date
- 2005-09-26
- Last Posted Date
- 2008-06-26
- Lead Sponsor
- The George Institute
- Target Recruit Count
- 404
- Registration Number
- NCT00226096
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺Royal Melbourne Hospital, Melbourne, Victoria, Australia
Treatment of Supine Hypertension in Autonomic Failure
- Conditions
- Interventions
- Drug: PlaceboDrug: ClonidineDrug: Nitroglycerin transdermalDrug: Dipyridamole/ Aspirin (Aggrenox)Drug: Desmopressin (DDAVP)Drug: SildenafilDrug: NifedipineDrug: HydralazineDrug: HydrochlorothiazideDrug: BosentanDrug: DiltiazemDrug: EplerenoneDrug: guanfacineDietary Supplement: L-arginineDrug: captoprilDrug: carbidopaDrug: losartanDrug: metoprolol tartrateDrug: nebivolol hydrochlorideDrug: prazosin hydrochlorideDrug: tamsulosin hydrochlorideOther: Head-up tilt.Drug: aliskirenOther: Local heat stress
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 152
- Registration Number
- NCT00223717
- Locations
- 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
Will Decreased Noradrenergic Activity Normalize Information Processing in Patients With Schizophrenia?
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2013-12-20
- Lead Sponsor
- Birte Glenthoj
- Target Recruit Count
- 40
- Registration Number
- NCT00206986
- Locations
- 🇩🇰
Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup, Copenhagen NV, Denmark
Treatment Targets for Chronic Hypertension in Pregnancy
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Weill Medical College of Cornell University
- Registration Number
- NCT00194974
- Locations
- 🇺🇸
The New York PresbyterianHospital-Weill Medical College of Cornell University, New York, New York, United States
Clonidine for Neurocognitive Sequelae
- Conditions
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
The Addition of Clonidine to 0.2% Ropivacaine for Wound Instillation After Minor Lower Abdominal Surgery in Children
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2015-02-20
- Lead Sponsor
- Children's Hospital of Eastern Ontario
- Target Recruit Count
- 120
- Registration Number
- NCT00130091
- Locations
- 🇨🇦
Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) in Children
- Conditions
- Interventions
- First Posted Date
- 2002-03-05
- Last Posted Date
- 2009-05-21
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 122
- Registration Number
- NCT00031395
- Locations
- 🇺🇸
Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States
🇺🇸University of Rochester, Department of Neurology, Rochester, New York, United States
Novel Medications for Opiate Detoxification - 4
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- Yale University
- Registration Number
- NCT00000279
- Locations
- 🇺🇸
VA Connecticut Healthcare System, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.